Efficacy and Safety of Recombinant Human Brain Natriuretic Peptide in Improving Heart Failure after Acute Myocardial Infarction Based on Multimodal Data

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500108645

Enrollment

Unknown

Registered

2025-09-03

Start date

2025-09-09

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute heart failure

Interventions

Group of acute myocardial infarction with acute heart failure :NA

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age >= 20 years old, 100ng/L or NT-proBNP > 300ng/L.

Exclusion criteria

Exclusion criteria: Heart rate beats greater than 120 beats/min, history of previous heart failure, history of subsequent PCI, septic shock, malignancy, acute respiratory distress syndrome, severe renal insufficiency (creatinine > 450 µ mol/L), severe liver failure, autoimmune disease (systemic lupus erythematosus, etc.), significant mechanical outflow tract obstruction, severe anemia (hemoglobin < 7 g/dl), or pregnancy status.

Design outcomes

Primary

Measure	Time frame
Heart failure readmission rate within 30 days;NT-proBNP levels at 72h;	—

Secondary

Measure	Time frame
Rate of change of vital signs at 72 h;	—

Countries

China

Contacts

Public ContactPan Yilong

Shengjing Hospital of China Medical University

605313787@163.com+86 189 4025 3537

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026